BioLife Solutions Financials

BLFS Stock  USD 22.94  2.00  8.02%   
Based on the key indicators related to BioLife Solutions' liquidity, profitability, solvency, and operating efficiency, BioLife Solutions is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February. At this time, BioLife Solutions' Other Assets are comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 126.3 M in 2026, despite the fact that Retained Earnings are likely to grow to (286.5 M).
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

BioLife Solutions Balance Sheet Chart

At this time, BioLife Solutions' Other Assets are comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 126.3 M in 2026, despite the fact that Retained Earnings are likely to grow to (286.5 M).
Key indicators impacting BioLife Solutions' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio3.314.09
Significantly Down
Very volatile
Investors should never underestimate BioLife Solutions' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BioLife Solutions' cash flow, debt, and profitability to make informed and accurate decisions about investing in BioLife Solutions.

Net Income

(17.26 Million)

  
Build AI portfolio with BioLife Stock
Understanding current and past BioLife Solutions Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioLife Solutions' financial statements are interrelated, with each one affecting the others. For example, an increase in BioLife Solutions' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in BioLife Solutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioLife Solutions. Check BioLife Solutions' Beneish M Score to see the likelihood of BioLife Solutions' management manipulating its earnings.

BioLife Solutions Stock Summary

BioLife Solutions competes with Kestra Medical, Novocure, Azenta, STAAR Surgical, and Phreesia. BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington. Biolife Solutions operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 432 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS09062W2044
Business Address3303 Monte Villa
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.biolifesolutions.com
Phone425 402 1400
CurrencyUSD - US Dollar

BioLife Solutions Key Financial Ratios

BioLife Solutions Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets552.6M450.2M412.7M399.5M459.4M482.4M
Other Current Liab23.1M18.7M21.0M12.3M14.2M14.9M
Net Debt(43.0M)24.3M5.9M(65.2M)(58.7M)(55.8M)
Retained Earnings(105.0M)(246.9M)(313.3M)(335.1M)(301.6M)(286.5M)
Accounts Payable14.9M15.4M6.9M3.6M4.1M2.1M
Cash69.9M19.4M27.9M95.4M109.7M115.2M
Other Assets50K120.1M426.7M386.2M444.1M466.3M
Other Current Assets4.4M6.9M14.3M6.0M6.9M7.2M
Total Liab71.9M86.0M75.1M50.6M58.2M61.1M
Total Current Assets125.9M138.5M120.6M148.8M171.1M179.6M
Inventory28.3M34.9M43.5M29.0M33.4M35.0M
Net Receivables23.2M33.9M18.7M9.2M10.5M11.1M
Short Term Debt3.8M4.8M7.6M12.5M14.3M15.0M
Common Stock42K43K45K47K54.1K37.1K
Intangible Assets152.1M32.1M21.1M9.6M11.0M19.2M
Long Term Debt6.4M23.8M18.3M5.0M5.7M7.8M
Other Liab41.1M14.0M31.9M2.6M3.0M2.8M
Net Tangible Assets(12.2M)205.2M480.8M364.2M418.8M439.8M

BioLife Solutions Key Income Statement Accounts

The reason investors look at the income statement is to determine what BioLife Solutions' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202120222023202420252026 (projected)
Interest Expense485K687K1.8M719K826.9K868.2K
Total Revenue119.2M76.2M143.3M82.3M94.6M99.3M
Gross Profit37.7M53.8M46.8M53.7M61.7M64.8M
Operating Income(35.2M)(5.9M)(70.8M)(7.1M)(6.4M)(6.7M)
Ebit(29.5M)(144.1M)(57.5M)(7.1M)(6.4M)(6.7M)
Ebitda(16.7M)(124.2M)(45.2M)1.5M1.4M1.4M
Cost Of Revenue81.4M107.9M96.5M28.6M32.9M34.5M
Net Income(8.9M)(139.8M)(66.4M)(20.2M)(18.2M)(17.3M)
Income Tax Expense(20.1M)(5.2M)169K(38K)(34.2K)(35.9K)
Income Before Tax(29.0M)(4.8M)(66.3M)(11.4M)(10.3M)(9.8M)
Research Development11.8M14.8M18.8M7.9M9.1M9.6M
Net Interest Income(432K)(687K)(1.7M)(719K)(647.1K)(614.7K)
Tax Provision(20.3M)(5.0M)127K(38K)(43.7K)(45.9K)

BioLife Solutions Key Cash Accounts

202120222023202420252026 (projected)
Change In Cash(20.6M)(50.4M)16.0M59.9M68.9M72.4M
Free Cash Flow(13.2M)(18.9M)(18.9M)5.2M4.7M4.9M
Depreciation12.9M16.5M12.3M5.5M6.3M6.6M
Other Non Cash Items(364K)109.7M8.6M(8.0M)(9.2M)(8.7M)
Capital Expenditures8.4M10.4M6.4M3.2M3.7M3.9M
Net Income(7.6M)(139.8M)(66.4M)(20.2M)(18.2M)(17.3M)
End Period Cash Flow69.9M19.5M35.4M95.4M109.7M115.2M
Change To Inventory114K(6.6M)(8.6M)781K702.9K738.0K
Net Borrowings(2.9M)17.8M(498K)(6.6M)(5.9M)(5.6M)
Change To Netincome15.0M(1.2M)(9.0M)114.8M132.0M138.6M
Investments(12.6M)(58.1M)(1.0M)58.3M67.0M70.4M

BioLife Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining BioLife Solutions's current stock value. Our valuation model uses many indicators to compare BioLife Solutions value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioLife Solutions competition to find correlations between indicators driving BioLife Solutions's intrinsic value. More Info.
BioLife Solutions is rated third in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, BioLife Solutions' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value BioLife Solutions by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from BioLife Solutions' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioLife Solutions current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLife Solutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy BioLife Stock please use our How to Invest in BioLife Solutions guide.At this time, BioLife Solutions' Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 697.46 in 2026, whereas Tax Provision is likely to drop (45.9 K) in 2026.
 2023 2024 2025 2026 (projected)
Total Operating Expenses117.6M60.8M69.9M73.4M
Cost Of Revenue96.5M28.6M32.9M34.5M

BioLife Solutions fundamental ratios Correlations

0.970.991.00.92-0.51-0.830.750.780.990.280.980.870.950.760.970.950.930.960.830.950.830.720.260.20.51
0.970.980.960.98-0.36-0.760.840.640.980.120.940.740.880.810.910.970.980.890.880.950.90.590.250.180.55
0.990.980.980.94-0.38-0.860.780.70.980.190.980.810.940.820.960.980.960.940.880.980.880.710.280.20.6
1.00.960.980.91-0.54-0.820.740.80.990.30.980.880.950.750.970.930.910.960.80.940.810.730.260.180.48
0.920.980.940.91-0.28-0.690.910.550.940.150.870.680.820.770.830.961.00.840.910.90.960.460.250.170.66
-0.51-0.36-0.38-0.54-0.280.4-0.04-0.9-0.43-0.43-0.47-0.8-0.57-0.24-0.53-0.26-0.24-0.64-0.07-0.36-0.07-0.51-0.07-0.020.16
-0.83-0.76-0.86-0.82-0.690.4-0.42-0.69-0.78-0.03-0.88-0.8-0.92-0.83-0.93-0.81-0.72-0.88-0.67-0.92-0.6-0.88-0.28-0.16-0.57
0.750.840.780.740.91-0.04-0.420.270.810.270.680.410.580.510.60.820.90.590.830.680.950.170.190.110.65
0.780.640.70.80.55-0.9-0.690.270.710.430.780.970.830.50.820.60.540.890.420.670.370.780.180.160.13
0.990.980.980.990.94-0.43-0.780.810.710.260.970.80.910.750.940.950.940.910.850.940.860.670.260.190.5
0.280.120.190.30.15-0.43-0.030.270.430.260.230.430.24-0.290.230.150.110.310.090.050.20.20.030.060.09
0.980.940.980.980.87-0.47-0.880.680.780.970.230.870.960.780.990.950.890.960.820.960.790.810.290.220.5
0.870.740.810.880.68-0.8-0.80.410.970.80.430.870.920.610.910.740.670.960.570.790.540.820.230.180.35
0.950.880.940.950.82-0.57-0.920.580.830.910.240.960.920.80.990.870.830.980.710.950.720.830.270.120.52
0.760.810.820.750.77-0.24-0.830.510.50.75-0.290.780.610.80.80.790.790.750.690.880.660.630.190.070.52
0.970.910.960.970.83-0.53-0.930.60.820.940.230.990.910.990.80.910.850.980.770.960.730.860.280.190.51
0.950.970.980.930.96-0.26-0.810.820.60.950.150.950.740.870.790.910.970.880.960.950.910.650.260.280.65
0.930.980.960.911.0-0.24-0.720.90.540.940.110.890.670.830.790.850.970.840.920.920.960.490.260.170.67
0.960.890.940.960.84-0.64-0.880.590.890.910.310.960.960.980.750.980.880.840.740.920.730.80.260.190.51
0.830.880.880.80.91-0.07-0.670.830.420.850.090.820.570.710.690.770.960.920.740.830.890.50.220.370.64
0.950.950.980.940.9-0.36-0.920.680.670.940.050.960.790.950.880.960.950.920.920.830.820.750.260.180.61
0.830.90.880.810.96-0.07-0.60.950.370.860.20.790.540.720.660.730.910.960.730.890.820.340.230.130.79
0.720.590.710.730.46-0.51-0.880.170.780.670.20.810.820.830.630.860.650.490.80.50.750.340.30.220.26
0.260.250.280.260.25-0.07-0.280.190.180.260.030.290.230.270.190.280.260.260.260.220.260.230.3-0.080.35
0.20.180.20.180.17-0.02-0.160.110.160.190.060.220.180.120.070.190.280.170.190.370.180.130.22-0.080.03
0.510.550.60.480.660.16-0.570.650.130.50.090.50.350.520.520.510.650.670.510.640.610.790.260.350.03
Click cells to compare fundamentals

BioLife Solutions Account Relationship Matchups

BioLife Solutions fundamental ratios Accounts

202120222023202420252026 (projected)
Total Assets552.6M450.2M412.7M399.5M459.4M482.4M
Other Current Liab23.1M18.7M21.0M12.3M14.2M14.9M
Net Debt(43.0M)24.3M5.9M(65.2M)(58.7M)(55.8M)
Retained Earnings(105.0M)(246.9M)(313.3M)(335.1M)(301.6M)(286.5M)
Accounts Payable14.9M15.4M6.9M3.6M4.1M2.1M
Cash69.9M19.4M27.9M95.4M109.7M115.2M
Other Assets50K120.1M426.7M386.2M444.1M466.3M
Other Current Assets4.4M6.9M14.3M6.0M6.9M7.2M
Total Liab71.9M86.0M75.1M50.6M58.2M61.1M
Total Current Assets125.9M138.5M120.6M148.8M171.1M179.6M
Inventory28.3M34.9M43.5M29.0M33.4M35.0M
Net Receivables23.2M33.9M18.7M9.2M10.5M11.1M
Short Term Debt3.8M4.8M7.6M12.5M14.3M15.0M
Common Stock42K43K45K47K54.1K37.1K
Intangible Assets152.1M32.1M21.1M9.6M11.0M19.2M
Long Term Debt6.4M23.8M18.3M5.0M5.7M7.8M
Other Liab41.1M14.0M31.9M2.6M3.0M2.8M
Net Tangible Assets(12.2M)205.2M480.8M364.2M418.8M439.8M
Today, most investors in BioLife Solutions Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioLife Solutions' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BioLife Solutions growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.79

At this time, BioLife Solutions' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

BioLife Solutions January 28, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of BioLife Solutions help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioLife Solutions. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioLife Solutions based on widely used predictive technical indicators. In general, we focus on analyzing BioLife Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioLife Solutions's daily price indicators and compare them against related drivers.

Additional Tools for BioLife Stock Analysis

When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.